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Abstract
Increasing number of genetic studies suggest that the pathogenesis of Parkinson’s disease
(PD) and cancer may involve similar genes, pathways, and mechanisms. The differen‐
ces in the pathological and cellular mechanisms, and the associated genetic mutations,
may result in two such divergent diseases. However, the links between the molecular
mechanisms that cause PD and cancer remain to be elucidated. This article appraises the
overlapping molecular features of these diseases and discusses the implications for
prevention and treatment. We propose that chronic inflammation (CI) in neurons and
tumors contributes to a microenvironment that favors the amassing of DNA mutations
and facilitating disease formation. CI may therefore play a key role in the development
of PD and cancer, and provide a link between these two diseases.
Keywords: Parkinson’s disease, cancer, chronic inflammation, neurodegenerative dis‐
ease, genetic mutation
1. Introduction
Parkinson’s  disease  (PD)  is  the  second  most  common  neurodegenerative  disease,  after
Alzheimer’s  disease  [1].  Typical  symptoms  include  static  tremors,  muscle  rigidity,  and
bradykinesia. These are caused by the premature death of dopaminergic neurons in the midbrain.
The motor symptoms can be treated with dopaminergic drugs; however, the effectiveness
diminishes as the severity of the clinical symptoms increases due to the development of the
primary neuro-degeneration [2]. In contrast, cancer is a type of selectively advantageous cells
with clonal proliferation. Although the two may appear distinctive, early epidemiological
surveys have shown a connection between them. In 1954, Doshay [3] reported that the cancer
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incidence rate was lower among PD patients, but the reason for this was undistinguishable.
Later, several epidemiological studies of cancer showed that the incidence of cancer was
generally low among PD patients, regardless of whether they smoke or not [4]. However, the
incidence of thyroid cancer, breast cancer, and melanoma was relatively high [5]. A recent study
covering 219,194 people with PD displayed that the rate ratio (RR) for all subsequent primary
malignant cancers combined was 0.92 [95% confidence interval (CI): 0.91–0.93], including
increased RRs (p  <  0.05) of breast cancer and melanoma cancer, and decreased RRs of 11 cancers
[6]. This has been the most commanding epidemiological evidence for a connection between
PD and cancer. Surely, there is a difference between association and causality, and it has been
proposed that the association between PD and skin cancer could be linked to the way of therapy,
such as Levodopa treatment, rather than with the disease itself. However, some observations
did not support the causality [7, 8]. Moreover, some people thought that the low incidence of
cancer in PD patients comes from the negative relationship between PD and smoking [4]. This
may widely explain the decrease of smoking-related cancers, but the reduction of non-smok‐
ing-related cancers cannot be resolved.
The unusual epidemiological relation between PD and cancer has drawn the attention of many
investigators. The genetic assessment encouraged an additional understanding: most of these
familial PD genes had been found and summarized to be associated with cancer (Table 1).
Mutations found in parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7), and LRRK2 (PARK8) might
cause distinctive significances and consequences of PD and cancer, respectively, in different
types of cells [9]. PD and cancer have been discovered to share a PI3K/AKT/mTOR pathway,
which is a central mechanism of cell growth and proliferation that mainly functions through
modulating protein synthesis and responding both intrinsic and environmental stress
promptly [10]. Currently, more than 12 loci were found to be related to familial PD [11]. Among
these, six genes have been cloned. The monogenic forms of PD display both autosomal
dominant and recessive modes of inheritance, and account for 1–3% of late-onset disease and
approximately 20% of young-onset disease [1, 12]. PD-related genes are involved in a series of
cellular mechanisms including misfolding and degradation of proteins, mitochondrial
damage, oxidative stress response, cell cycle control, and DNA repair. These all play a vital
role in both PD and cancer. Understanding of the functions of these genes in cell survival and
cell death might help to reveal the connection between the two diseases.
Gene PD locus Chromosome
location
Inheritance 
in PD*
Expression in
cancer
Proliferation
in Cancer†
Cancer
α-
Synuclein 
PARK1/
PARK4
4q21–q23 AD Overexpressed
(not express in
normal tissue)
+ Brain tumors [74]
Melanoma [75]
Ovary cancer [76]
Parkin PARK2 6q25.2–q27 AR Decreased§ − Glioblastoma [9]
Colon cancer [9]
Lung cancer [9]
UCHL1 PARK5 4p14 AD Silenced − Nasopharyngeal carcinoma
[77]
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Gene PD locus Chromosome
location
Inheritance 
in PD*
Expression in
cancer
Proliferation
in Cancer†
Cancer
(via CpG
methylation)
Colorectal cancer [78]
PINK1 PARK6 1p35–p36 AR Decreased§ − Breast cancer [79]
DJ-1 PARK7 1p36 AR Overexpressed + Non-small-cell lung cancer
[80]
LRRK2 PARK8 12p11.2–q13.1 AD Overexpressed + Papillary renal cell carcinoma
[64],
Thyroid cancer [64]
*AD, autosomal dominant; AR, autosomal recessive
§The telomeric end of chromosome 1p is subject to frequent deletion and rearrangement in many cancers
† +/− denotes proliferation and antipoliferation.
Table 1. Parkinson’s disease involved genes identified in cancer.
If genetic defect was “the match that lights the fire” of PD and cancer, chronic inflammation
(CI) might supply “the fuel that feeds the flames.” Over the past decades, the insight on
cytokine and chemokine network has contributed to invention of a series of cytokine/chemo‐
kine antagonists used for inflammatory diseases. The first clinic practice, tumor necrosis factor
antagonists, has shown encouraging efficacy [13]. CI is considered as a driving force behind
many chronic diseases including cancerization and neurodegeneration. In PD, there are many
activated microglia surrounding the lost neuron, and experiments have shown that inflam‐
matory reaction does help killing neurons [14]. Epidemiological surveys have shown that
taking non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of PD develop‐
ment. CI has long been known to mediate a wide variety of illnesses, including neurodege‐
nerative disease and malignant tumors [15]. In 1863, Rudolf Virchow noticed leucocytes in
neoplastic tissues and proposed a connection between inflammation and cancer. The role for
inflammation in tumorigenesis is now mostly accepted, and it has become an evident that an
inflammatory microenvironment is an essential piece for most tumors [16]. Inflammatory
mediators in the microenvironment of CI not only benefit cancer cells proliferation and escape
from immunological surveillance but also cause a large number of random mutations [17].
Amassing research evidence supports the view that inflammatory mediators, some of that are
direct mutagens, directly or indirectly downregulate DNA repair pathways and cell cycle
checkpoints, consequently destabilizing cell genome and contributing to the accumulation of
random genetic alterations. Thus, inflammation is considered as the seventh most important
sign of cancer [18].
The cellular pathways and its associated mechanisms (Figure 1) that involve genes common
to PD and cancer have been discussed in our previous paper [19]. In this manuscript, we further
explain the environmental factors that cause PD and cancer from the perspective of CI and
related genes to provide a better understanding and treatment options of these two diseases.
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To emphasize the multiple pathological functions of these gene mutations, they are dis‐
cussed separately.
Figure 1. Overlapping genes and cellular pathways between PD and cancer.The biological connection of PD and can‐
cer mainly includes five fields: (a) misfolding and degradation of proteins, (b) mitochondrial damage and oxidative
stress response, (c) CI, (d) cell cycle control and DNA repair, and (e) PI3K/AKT/mTOR pathway regulation. The α-syn‐
uclein polymer attributed to SNCA multiplication is the main component of LBs. SNCA mutations alter the normal
function of α-synuclein, which activates the PI3K/AKT/mTOR pathway and promotes cell proliferation. Under the cas‐
cade of phosphorylating AKT, PINK1, and LRRK2 can also activate mTOR. PARK2 and UCH-L1 mutations disrupt the
degradation function of ubiquitin proteasome system (UPS) for the misfolded and aggregated α-synuclein, cyclin E,
and p53. PINK1 and DJ-1 mutations result in the overproduction of ROS and oxidative stress in mitochondria, damag‐
ing neurons, and stimulating cell proliferation. COX2 and CARD15 mutations activate the NF-kB pathway and induce
CI, leading to genetic mutations and oxidative stress. The different cellular backgrounds of cancer cells and neurons
(mitotic vs. post-mitotic cells) bring completely distinct reactions to external stimuli and internal changes: some under‐
go cell proliferation and others neuron death. The final results are two serious diseases: cancer and Parkinson’s dis‐
ease.
2. Chronic inflammation
The blood–brain barrier (BBB) prevents the lymphatic infiltration and neurotoxins diffusion
from the blood to the CNS. Conventionally, the CNS was regarded as the immunological
restriction due to its limited inflammatory reaction and lymphatic infiltration. Nonetheless,
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accumulating evidence indicates that the CNS actually is the immunological specialization by
the resident innate immune cell in the brain: microglia. Activated microglia could prevent the
CNS injury from pathogenic factors (physiological disrupt and toxic insult) through releas‐
ing a number of cytokines and chemokines [20]. These inflammatory mediators could trigger
or modulate the remove of neurotoxins and inhibit their detrimental effects. Thus, acute
inflammatory responses are consider to be beneficial, but long-term, high-level CI can severely
damage the body. Two of the pathological characteristics of PD are loss of dopaminergic
neurons and accumulation of LBs in the nigrostriata of the midbrain. LBs are abnormal
intracytoplasmic filamentous aggregates of α-synuclein present, respectively, in neurons and
axons. Recent studies have shown that neurons able to release α-synuclein oligomers, which
can bind to toll-like receptors (TLR) to activate microglia, activating the nuclear factor kappa
B (NF-kB) pathway, and releasing of inflammatory factors. These immune factors not only act
directly on dopaminergic neurons to cause neuronal death but also aggravate the inflamma‐
tory reaction and continue to activate microglia. Activated microglia surround dead neurons
in the substantia nigra pars compacta (SNc) of PD patients. Studies have shown that inhibi‐
tion of microglia cascade reactions can prevent degradation of neurons [21]. Increasing studies
demonstrated that there was a positive correlation between SNc cell loss and microglia
activation in both animal models and PD patients. Timing analysis displayed that reduce
microglial activation can rescue SNc neurons loss in animal models, suggesting an active effect
of microglia in killing SNc cell following a range of stimuli. It is increasingly clear that
activation of microglia is a highly localized inflammatory reaction rather than generalized.
Even though the degenerating neuronal terminals of SNc cell cannot stimulate the similar
response but only the dopaminergic neurons in the SNc [22]. Therefore, cell death of PD
directly relates to a substantial increase of microglia activation. At the same time, overpro‐
duction of free radicals (superoxide and peroxynitrite) damages the balance of the redox
potential of neurons and acts on biomacromolecules to modulate their roles, or causes lipid
peroxidation leading to cell death eventually. Alternatively, microglia might kill SNc cells by
producing other noxious compounds including cytokines and proinflammatory prostaglan‐
dins. Patients with PD have selective degeneration of neurons in the SNc accompanied by
microglial activation and a challenged immune system.
The presence of activated microglia in PD might reflect a scavenging role in the wake of a
primary pathologic process. However, evidence for a more sinister role comes from animal
models of PD. MPTP, 6-OHDA, lipopolysaccharide, rotenone, viruses, and SNc extracts all can
lead to degeneration of the dopaminergic neurons and loss of striatal dopamine in primates,
rodents, and other species [23]. Each of them can cause an inflammatory response that
associated with the enhancement of microglia activation in the SNc. The best evidence for the
significance of inflammation during neoplastic progression maybe come from study of cancer
risk among long-term users of aspirin and NSAIDs. A big prospective study of hospital
workers indicated that the incidence of PD in chronic users of over-the-counter NSAIDs which
scavenge free oxygen radicals and inhibit cyclooxygenase (COX) activity was 46% lower than
that of age-matched non-users [24]. Inhibition of COX-mediated dopaminergic neurons
oxidation, as well as inhibition of microglial-derived toxic mediator production, is likely to be
among the mechanisms that contribute to decreased incidence of PD in chronic NSAIDs
Chronic Inflammation Connects the Development of Parkinson’s Disease and Cancer
http://dx.doi.org/10.5772/63215
93
users [25]. Therapeutically, these findings raise the possibility that early involvement with
NSAIDs or similar anti-inflammatory therapy may be neuroprotective and could delay or
prevent onset of PD. That anti-inflammatory medications downregulate microglial respons‐
es to a toxic insult and directly reduce neuronal loss strongly, which indicates that localized
inflammation is pathogenic in the SNc rather than merely a late response to neuronal death.
3. NOD2
Crohn’s disease (CD), also known as regional enteritis, is a type of inflammatory bowel disease.
In 2001, three laboratories found CD associate with genetic variants. Nucleotide-binding
oligomerization domain protein 2 (NOD2) also known as caspase recruitment domain
protein 15 (CARD15) is a protein that in humans which is encoded by the CARD15 gene located
on human chromosome 16q12 [26–28]. Approximately 40% of CD patients in the Western
countries carry at least one of these three SNPs: R702W, G908R, and L1007fsinsC, and
heterozygous mutation of any of these SNPs increases CD risk 2–4 times, whereas multiple-
locus heterozygous mutations or homozygous mutations may lead to a CD risk higher than
20 times. However, it has been reported that none of these three SNPs was involved in CD
among Chinese (Han) [29], Korean [30], and Japanese patients [31]. NOD2, encoded by
CARD15, is the receptor of muramyl peptides (MDP), a component of bacterial peptidogly‐
can. Binding of MDP and NOD2 activates NF-kB, and inflammatory reaction occurs. It has
also been shown that CARD15 mutation plays a role in innate immune system and pathogen
recognition in terms of other complex polygenic diseases. In 2007, Bialecka [32] showed that
the three SNPs of CARD15 (R702W, G908R, and L1007fsinsC) were significantly correlated
with PD in the Polish population. Using RFLP, our group found P268S, another SNP of
CARD15, to be a risk factor for Chinese PD. In addition, Crane et al. [33] reported that P268S
was related to susceptibility of ankylosing spondylitis. Proell et al. [34] performed sequence
comparison and found that NOD2 shared a high degree of similarity with apoptotic pro‐
tease activating factor 1 (Apaf-1). They simulated the homologous structure of NOD2 based
on Apaf-1 structure and found that P268S was located at the connexon (ligand-binding
position) before the first helix of the NOD. Replacing Pro with Ser changed the conforma‐
tion of the connexon and affected its binding to the substrate.
Whether the CD’s-associated CARD15 mutations lead to a loss or gain of function of the NOD2
receptor is subject to controversy, and by which mechanisms, this change in function might
increase the susceptibility to CD which is still under investigation. Patients with CD are known
to have an increased risk of developing colorectal cancer [35]. CARD15 mutations may also
increase the susceptibility of developing colorectal cancer in Caucasians without CD [36, 37].
These observations suggested that immune system mechanisms were involved in the
pathogenesis of cell damage in CD and also provided evidence for an ongoing active patho‐
logic process. Inflammation can be triggered by invading microbes and also be initiated from
within the organism, by diseases affecting the nervous system. There are three common
outcomes of inflammation. The offending agent or process is inactivated and the injury
repaired. The host loses the battle and dies or suffers irreparable tissue damage. Neither the
organism nor the injurious process prevails, resulting in a prolonged battle that provides fertile
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ground for the development of chronic inflammatory conditions. The last outcome may relate
closely to neurodegenerative diseases and cancer, two of the greatest public health problems
of this century [38].
4. COX2
COX is the central enzyme in prostaglandin biosynthesis. There are two different isoforms of
COX: COX-1 and COX-2. Constitutive expression of COX-1 is commonly found in many
tissues. Because COX-1 is responsible for the biosynthesis of prostaglandins which regulate
some physiological homeostasis, including modulation of renal blood flow and preservation
of the gastric mucosa. Normally, COX-2 could not be discovered in most tissues except for
stimulating by some mitogenic and inflammatory mediators [39]. COX2 is not only key to the
synthesis of prostaglandin in inflammatory reactions but also an important contributor to the
degradation of neurons in PD. Inhibiting COX2 activity in mice and rats can alleviate neuronal
death caused by MPTP [40] and 6-ODHA [41], respectively. Macrophages, neurons, and glial
cells in the central nervous system can all express COX2. Unlike COX1, which is constitutive‐
ly expressed, COX2 expression is induced by inflammatory conditions. The COX2 level in the
dopaminergic neurons of PD patients is elevated, and prostanoid and ROS produced by COX2
can directly act on dopaminergic neurons causing cell toxicity [42]. The role of COX2 in
inflammation and neuronal degradation has yet to be verified. However, it has been shown
that NSAIDs nonselectively inhibit the activities of COX1 and COX2, thus reducing prosta‐
glandin production and promoting clearance of ROS. An epidemiological survey has re‐
vealed that individuals who take NSAIDs have a lower risk of PD than those who do not [25].
However, there has not been any report on the effects of specific COX2 inhibitors on the
occurrence and development of PD.
COX-2, the inducible isoform of prostaglandin H synthase, has been implicated in the growth
and progression of a variety of human cancers [43]. There are many evidence support that
COX-2 is involved in the development of cancer. Because the overexpression of COX-2 is
commonly found in the premalignant and malignant tissues. The most powerful findings from
genetic studies support the view that it exists a cause-and-effect relationship between COX-2
and tumorigenesis. Multiple lines of evidence indicate that COX-2 is a bona fide pharmacolog‐
ical target for anticancer therapy. Epidemiologic studies have shown a 40–50% reduction in
mortality from colorectal cancer in individuals who take NSAIDs on a regular basis com‐
pared with those not taking these agents [44]. COX-2, an inducible enzyme with expression
regulated by NF-kB, mediates tumorigenesis. COX2 can activate not only the NF-kB path‐
way, but also p38 and Jnk in the MAPK pathway [45]. High levels of COX2 have been found
in many cancers, particularly colon cancer [46]. COX-2 is also expressed in 93% of melano‐
mas, with a moderate-to-strong expression in 68% [47]. COX2 can decrease the level of
arachidonic acid and inhibit cell apoptosis. It can also increase prostaglandin production and
promote cell growth and differentiation. These phenomena were also observed in the clinical
effect of selective COX2 inhibitors in the market [48, 49].
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5. LRRK2
Leucine-rich-repeat kinase 2 (LRRK2) is a large gene, 144 kb in length, containing 51 exons and
encoding a multi-domain kinase composed of 2527 amino acids. LRRK2 is expressed in many
organs and tissues, including the brain. In 2004, two laboratories reported that LRRK2
mutations were related to PD [50, 51]. More than 40 LRRK2 mutations, almost all missense,
have been found [52]. However, the nosogeneses of many mutations remain unclear. LRRK2
mutations account for 10% of familial PD and 3.6% of sporadic PD, suggesting strong modifiers
of LRRK2 disease [53]. LRRK2 is a large protein (280KDs). It can activate AKT, an upstream
element of the mTOR pathway, thus decreasing the anti-apoptosis activity mediated by AKT
and promoting neuronal death [54]. Gene structure studies showed that LRRK2 protein was
consist of five conserved domains, including a leucine-rich repeat (LRR) domain, a Roc GTPase
domain, a C terminal of Roc (COR) domain, a MAPKKK mixed-lineage protein kinase domain,
and a WD40 domain [55, 56]. LRRK2 contains multiple sets of internal repeats, each of which
is predicted to adopt a distinct structure. Such repeats, which occur in 14% of all prokaryotic
and eukaryotic proteins, commonly serve as platforms for protein interactions [57]. LRRK2
gene was discovered as part of an evolutionarily conserved family of proteins marked by
GTPase (Guanosine triphosphatase) domains usually encoded together with kinase domains
[55]. The G2019S mutation in the LRRK2 is the single most common autosomal dominantly
inherited PD gene defect. The LRRK2 protein is a scaffolding-type protein kinase, and G2019S
is thought to lead to the disease by increasing the LRRK2 kinase activity resulting in in‐
creased phosphorylation of as yet mostly hypothetical targets, although whether all muta‐
tions in LRRK2 have the same biochemical mechanism is uncertain [58]. Missense mutations
in both the kinase and GTPase domain in LRRK2 cause late-onset PD with clinical and
pathological phenotypes nearly indistinguishable from idiopathic disease, possibly through
the upregulation of LRRK2 kinase activity [59]. Because the clinical phenotype ensuing from
LRRK2 mutations resembles idiopathic PD, LRRK2 has emerged as, perhaps, the most relevant
player in PD pathogenesis identified to date [60]. One of the consistent pathological features
of patients with LRRK2 mutations is α-synuclein-positive LBs pathology [61]. Besides G2019S,
there are only a handful of proven pathogenic mutations in LRRK2, which is rather surpris‐
ing given its large size. Multiple pathogenic mutations (I1371V, R14441C, R1441G, R1441H,
Y1699C, Y1699G, G2019S, and I2020T) are located within the GTPase and the kinase do‐
mains or within the COR domain. This structural feature can be used as a target in the design
of drugs that treat PD [62]. Many of the LRRK2 kinase inhibitors identified to date were
discovered by using libraries of defined kinase inhibitors [63]. As with any kinase inhibitor
development for human use, issues related to safety will need to be carefully evaluated. This
is particularly important for a chronic disease such as PD.
More directly supporting a role of LRRK2 in cancer, chromosomal amplification of the LRRK2
locus is required for oncogenic signaling in papillary renal and thyroid carcinomas [64].
Genetic studies have implicated LRRK2 in the pathogenesis of several human diseases,
including cancer and CD [65–67]. In 2011, Liu et al. [68] found that LRRK2 could suppress the
activity of the transcription factor Nuclear factor of activated T-cells (NFAT). Overexpres‐
sion of LRRK2 led to increased retention of NFAT in the cytosol. When LRRK2 was knocked
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out, NFAT in the cytosol was translocated to the nucleus and transcriptionally activated the
expression of genes encoding cytokines and other key proteins involved in triggering
inflammatory responses. It was firstly proposed that LRRK2 might play an important role in
the signal pathway that induced CD. Liu and co-workers highlighted the possibility that the
M2397T (replacement of methionine 2397 with threonine) polymorphism may alter the steady-
state abundance of LRRK2, which is distributed in many tissues and brain regions, generally
at low abundance. In addition, the structure of LRRK2 is similar to that of carcinogen B-RAF.
Therefore, it can act on the MAPK pathway. G2019S, a common LRRK2 mutation in PD, can
increase the risk of non-skin cancer in Jews by three times [69]. A complex role for LRRK2 in
multiple cellular processes is perhaps not surprising, because LRRK2 has multiple domains
and is both an active kinase and a GTPase [70]. Binding the different LRRK2 domains and
different ligands may have different functions, preventing them from connecting closely with
PD, inflammation, or cancer. To understand the roles of LRRK2 in human disease, the best
place to start is with examination of the genetics linked to these diseases. Various coding
changes in the open reading frame of LRRK2 are linked to disease. In PD, these mutations
result in functional changes in LRRK2, although no clear pattern to these changes has emerged.
LRRK2 is involved in many diseases result from the distinct influence of genetic mutations.
These variants not only change the potential of LRRK2 to interact with upstream regulators or
downstream effector, but also can alter the biological functions of LRRK2. The discovery of
more LRRK2 functions and a deeper understanding of its pleiotropism should provide the
research community with more insight into the pathological functions of the same protein in
different diseases. Every protein may have more than one function and may play completely
different roles in different diseases. Targeted therapies with minimal side effects may be
developed based on the functions of these proteins in different signal pathways.
6. Perspective and conclusion
Increasingly epidemiologic findings demonstrated the correlation between cancer and PD in
recent years, but the conclusions were not completely consistent. This is because of the
differences of study management. Our understanding of the control of signaling pathways is
further advanced in cancer studies compared to neurodegeneration. As a result, many small
molecule inhibitors have been approved as anticancer agents or are currently being tested in
clinical trials. In 2010, Datamonitor Inc. (USA) estimated that there were over 1.5 million PD
patients in the USA, Japan, France, Germany, Italy, Spain, and UK combined, one-third of them
in the USA. With the increasing aging of world population, the incidence of PD is increasing
yearly [71]. Medication is usually the first option in the treatment of PD. Levodopa is current‐
ly the most effective medication, but long-term use can reduce the effectiveness of treatment
and cause complications such as motor dysfunction. Thus, discoveries in cancer research are
likely to provide a solid base upon which scientists will study the pathophysiology of
neurodegenerative diseases, especially PD.
The origins of the association and interplay between cancer and PD are still a matter of debate,
but increasing epigenetic modifications such as DNA acetylation, DNA methylation, and
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miRNA scan conspire with genetic alterations in disease pathogenesis [72]. Recently, Gehrke
et al. [73] found that LRRK2 mutation in Drosophila model could have an antagonist effect on
two miRNAs: let-7, a known tumor suppressor, and miR-184, a mediator of neurological
development. This led to E2F1/DP over-expression, causing the cells to reenter the cell cycle.
These will help us develop an understanding of these two diseases from opposing angles.
Although, cancer and PD seem to have little in common, one due to enhanced resistance to
cell death and the other due to premature cell death. However, the more we learn about the
molecular genetics and cell biology of cancer and PD, the greater the overlap between these
disorders appears. Both cancer and PD are thought to be the result of the interaction of genetic
and environmental factors. The difference is that different reactions occur based on different
cellular backgrounds: cell division and cell death. The inflammation hypothesis is consid‐
ered one explanation for PD and cancer. The immune factor and ROS released from chronic
inflammatory reactions not only promote the occurrence of the disease but also cause cellular
DNA to accumulate mutations more easily, forming proteins with aberrant functions. In the
end, interactions between genes and the environment cause the diseases. Recently, our group
found that P268S in CARD15 may be a risk factor for PD, and Liu and co-workers provide
evidence that LRRK2 also has a role in a signaling pathway linked with the pathogenesis of
Crohn’s disease, an inflammatory bowel disease. These findings both implied a correlation
between PD and inflammation.
Most degenerative diseases of the brain are incurable and the study of tissue from the brains
of people with significant neurodegeneration is difficult, so the postmortem specimen is
probably the most valuable research material. However, academic and clinic of cancer research
have accumulated a wide range of achievement in the past long time, and these results and
experience must be important and beneficial to neurodegeneration study. Understanding the
nature of their relationship must help scientist find novel and more efficacious therapeutic
approaches for both diseases.
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